Venetoclax in patients with previously treated WM

ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy

Even late progressors with high risk factors in PRIMA prognostic index are more likely to die

Patient relevant outcomes and advocacy

The mutational landscape of AML

Lymphoma guidelines in Venezuela

Brentuximab vedotin with chemo for relapsed Hodgkin lymphoma

EHA 2018: Research, collaboration and working towards cures

Educational focus on immunotherapy at EHA

ADC polatuzumab vedotin in combinations for relapsed lymphoma

iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia

EHA 2018: Initial results of the INSIGHT trial in multiple myeloma